Amanote Research
Register
Sign In
18. In Vivo Expansion of a Recipient Population of Cell Carriers Allows for Highly Effective Systemic Delivery of Oncolytic Reovirus Even in the Presence of Neutralizing Antibody
Molecular Therapy
- United States
doi 10.1016/s1525-0016(16)34353-2
Full Text
Open PDF
Abstract
Available in
full text
Categories
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Date
May 1, 2013
Authors
Unknown
Publisher
Elsevier BV
Related search
Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy
Cancer immunology research
Cancer Research
Immunology
Cytokine-Induced Killer Cell Delivery Enhances the Antitumor Activity of Oncolytic Reovirus
PLoS ONE
Multidisciplinary
Achieving Systemic Delivery of Oncolytic Viruses
Expert Opinion on Drug Delivery
Pharmaceutical Science
Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning With Cyclophosphamide-Mediated Treg Modulation and Interleukin-2
Clinical Cancer Research
Cancer Research
Oncology
An Effective Cell-Penetrating Antibody Delivery Platform
JCI insight
Medicine
Harnessing the Power of Cell-Penetrating Peptides: Activatable Carriers for Targeting Systemic Delivery of Cancer Therapeutics and Imaging Agents
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
Medicine
Bioengineering
Nanotechnology
Biomedical Engineering
Nanoscience
Recombinant Adenoviral Delivery for in Vivo Expression of scFv Antibody Fusion Proteins
Gene Therapy
Molecular Medicine
Genetics
Molecular Biology
Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic
Cancer Research
Cancer Research
Oncology
Immunologic Studies in Insulin Resistance Ii. The Presence of a Neutralizing Factor in the Blood Exhibiting Some Characteristics of an Antibody
Journal of Clinical Investigation
Medicine
